Virpax Pharmaceuticals (VRPX) Competitors $0.01 0.00 (0.00%) As of 08/13/2025 02:29 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRPX vs. NAVB, SYRS, SCPS, EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, and AMPEShould you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Syros Pharmaceuticals (SYRS), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry. Virpax Pharmaceuticals vs. Its Competitors Navidea Biopharmaceuticals Syros Pharmaceuticals Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Virpax Pharmaceuticals (NASDAQ:VRPX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Which has higher earnings & valuation, VRPX or NAVB? Navidea Biopharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/ANavidea Biopharmaceuticals$8.13K6.16-$15.18MN/AN/A Do insiders & institutionals hold more shares of VRPX or NAVB? 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, VRPX or NAVB? Virpax Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Does the media prefer VRPX or NAVB? In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Virpax Pharmaceuticals Neutral Navidea Biopharmaceuticals Neutral Is VRPX or NAVB more profitable? Navidea Biopharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Virpax PharmaceuticalsN/A -1,554.34% -338.29% Navidea Biopharmaceuticals N/A N/A N/A Do analysts recommend VRPX or NAVB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryNavidea Biopharmaceuticals beats Virpax Pharmaceuticals on 6 of the 8 factors compared between the two stocks. Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRPX vs. The Competition Export to ExcelMetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14K$795.26M$5.57B$9.81BDividend YieldN/A4.84%4.62%4.12%P/E RatioN/A1.1829.8025.74Price / SalesN/A34.27460.01111.33Price / CashN/A19.5637.7558.93Price / Book0.016.578.496.01Net Income-$15.19M-$4.39M$3.25B$264.84M7 Day PerformanceN/A3.18%3.71%2.66%1 Month PerformanceN/A-1.27%4.03%1.56%1 Year PerformanceN/A19.76%35.47%29.07% Virpax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRPXVirpax PharmaceuticalsN/A$0.01flatN/A-99.9%$14KN/A0.007NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/AN/A$50K$8.13K0.0010SYRSSyros Pharmaceuticals4.0873 of 5 stars$0.00+9.1%$3.33+277,677.8%-99.9%$32K$386K0.00120Gap UpSCPSScopus BioPharmaN/A$0.00flatN/A+50.0%$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5KN/A0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+31.8%$3KN/A0.0020 Related Companies and Tools Related Companies NAVB Alternatives SYRS Alternatives SCPS Alternatives EVLO Alternatives CMRA Alternatives GNCAQ Alternatives GNCA Alternatives ARDS Alternatives STAB Alternatives AMPE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRPX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access